Physician profile
John A Adams
NPI 1750395570
$8,125.40
in general payments reported to CMS, 2019-2025
44 companies · $167 in 2025
The $167 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,255 · 2020: $2,728 · 2021: $2,173 · 2022: $339 · 2023: $362 · 2024: $102 · 2025: $167.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $631.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $630.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $964.77 | 2019-2024 | Airsupra, Farxiga |
| Teva Pharmaceuticals USA, INC. | $807.59 | 2019-2021 | |
| Abbvie INC. | $714.17 | 2020-2024 | |
| Pfizer INC. | $520.40 | 2019-2023 | |
| Lilly USA, LLC | $487.04 | 2019-2023 | Mounjaro |
| Biosense Webster, INC. | $446.55 | 2020 | |
| Amgen INC. | $437.78 | 2019-2023 | Otezla, Repatha |
| Novo Nordisk INC | $340.40 | 2019-2023 | Rybelsus, Ozempic, Wegovy |
| Janssen Pharmaceuticals, INC | $300.62 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $285.09 | 2019-2021 | |
| Amarin Pharma, INC. | $217.05 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $211.43 | 2019-2022 | |
| Esperion Therapeutics, INC. | $193.46 | 2020-2021 | |
| Procept Biorobotics Corporation | $166.81 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $166.23 | 2019-2023 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Adams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.